DMD play Exonics raises $40M series A

Exonics Therapeutics Inc. (Boston, Mass.) raised $40 million in a series A round from The Column Group. The company will use the financing to develop its preclinical CRISPR technology to treat Duchenne muscular dystrophy (DMD) and establish lab facilities in Cambridge, Mass.

The company launched in February with $5 million from CureDuchenne (see BioCentury, March 2)...